Biology of tumor necrosis factor type alpha (TNF-α);Biologia czynnika martwicy nowotworów typu alfa (TNF-α)

Polski Merkuriusz Lekarski

Volumn 21, Issue 124, 2006, Pages 358-361

  Korobowicz, Agnieszka ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Apoptosis; Gene; Inflammation; Neoplasm; Protein; TNF; TNF receptor; TNF

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MEMBRANE PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 2;

APOPTOSIS; BINDING AFFINITY; CELL ACTIVATION; CHROMOSOME 6; ENDOTHELIUM CELL; FIBROBLAST; GENE EXPRESSION; LYMPHOCYTE; MACROPHAGE; NEUTROPHIL; PROTEIN SYNTHESIS; REVIEW; RNA CLEAVAGE; RNA TRANSLATION; THYMOCYTE;

ANIMALS; APOPTOSIS; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; NF-KAPPA B; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33751059734     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Aggarwal B.B., Kohr W.J., Hass P.E. i wsp.: Human tumor necrosis factor. Production, purification, and characterization. J. Biol. Chem., 1985, 260, 2345-2354.
2. Aggarwal B.B., Samanta A., Feldmann M.: TNF-α. W: Cytokine Reference: A Compendium of Cytokines and Other Mediators of Host Defense. Vol. 1. Oppenheim J.J., Feldmann M. (red.). Academic Press, London 2000, 413-434.
3. Beyaert R., Vanhaesebroeck B., Declercq W. i wsp.: Casein kinase-1 phosphorylates the p75 tumor necrosis factor receptor and negatively regulates tumor necrosis factor signaling for apoptosis. J. Biol. Chem., 1995, 270, 23293-23299.
4. Burdan F., Szumilo J., Marzec B. i wsp.: Skeletal developmental effects of selective and nonselective cyclooxygenase-2 inhibitors administered through organogenesis and fetogenesis in Wistar CRL: (WI)WUBR rats. Toxicology, 2005, 216, 204-223.
5. Carswell E.A., Old L.J., Kassel R.L. i wsp.: An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci., USA, 1975, 72, 3666-3670.
6. Coley W.B.: The treatment of malignant tumors by repeated inoculations of erysipelas. With a report often original cases. 1893. Clin. Orthop. Relat. Res., 1991, 262, 3-11.
7. Creasey A.A., Doyle L.V., Reynolds M.T. i wsp.: Biological effects of recombinant human tumor necrosis factor and its novel muteins on tumor and normal cell lines. Cancer Res., 1987, 47, 145-149.
8. Fenton M.J., Vermeulen M.W., Clark B.D. i wsp.: Human pro-IL-1 beta gene expression in monocytic cells is regulated by two distinct pathways. J. Immunol., 1988, 140, 2267-2273.
9. Fantuzzi G.: Adipose tissue, adipokines, and inflammation. J. Allergy Clin. Immunol., 2005, 115, 911-919.
10. Furuya T., Salstrom J.L., Joe B. i wsp.: Polymorphisms of the tumor necrosis factor receptor type 1 locus among autoimmune susceptible and resistant inbred rat strains. Immunogenetics, 2001, 53, 427-429.
11. Goła̧b J., Jakóbisiak M., Lasek W. (red).: Immunologia. PWN, Warszawa 2004.
12. Gulubova M.V.: Expression of cell adhesion molecules, their ligands and tumour necrosis factor alpha in the liver of patients with metastatic gastrointestinal carcinomas. Histochem. J., 2002, 34, 67-77.
13. Holtmann H., Wallach D.: Down regulation of the receptors for tumor necrosis factor by interleukin 1 and 4 beta-phorbol-12-myristate-13-acetate. J. Immunol., 1987, 139, 1161-1167.
14. Hsu H., Shu H.B., Pan M.G. i wsp.: TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell, 1996, 84, 299-308.
15. Imamura K., Spriggs D., Ohno T. i wsp.: Effects of botulinum toxin type D on secretion of tumor necrosis factor from human monocytes. Mol. Cell Biol., 1989, 9, 2239-2243.
16. Jabbar S.A., Hoffbrand A.V., Wickremasinghe R.G.: Defects in signal transduction pathways in chronic B lymphocytic leukemia cells. Leuk. Lymphoma, 1995, 18, 163-170.
17. Jones E.Y., Stuart D.I., Walker N.P.: Structure of tumour necrosis factor. Nature, 1989, 338, 225-228.
18. Kunkel S.L., Spengler M., May M.A. i wsp.: Prostaglandin E2 regulates macrophage-derived tumor necrosis factor gene expression. J. Biol. Chem., 1988, 263, 5380-5384.
19. Lai W.S., Carballo E., Strum J.R. i wsp.: Evidence that tristetraprolin binds to AU-rich elements and promotes the deadenylation and destabilisation of tumor necrosis factor alpha mRNA. Mol. Cell Biol., 1999, 19, 4311-4323.
20. Liu Z.G.: Molecular mechanism of TNF signaling and beyond. Cell Res., 2005, 15, 24-27.
21. Logan T.F., Gooding W.E., Whiteside T.L. i wsp.: Biologic response modulation by tumor necrosis factor alpha (TNF alpha) in a phase Ib trial in cancer patients. J. Immunother., 1997, 20, 387-398.
22. Narhi L.O., Philo J.S., Li T. i wsp.: Induction of alpha-helix in the beta-sheet protein tumor necrosis factor-alpha: thermal- and trifluoroethanol-induced denaturation at neutral pH. Biochemistry, 1996, 35, 11447-11453.
23. Nedospasov S.A., Hirt B., Shakhov A.N. i wsp.: The genes for tumor necrosis factor (TNF-alpha) and lymphotoxin (TNF-beta) are tandemly arranged on chromosome 17 of the mouse. Nucleic Acids Res., 1986, 14, 7713-7725.
24. Nedwin G.E., Svedersky L.P., Bringman T.S. i wsp.: Effect of interleukin 2, interferon-gamma, and mitogens on the production of tumor necrosis factors alpha and beta. J. Immunol., 1985, 135, 2492-2497.
25. Newman G.G.: Teratogen update: clinical aspects of thalidomide embryopathy - a continuing preoccupation. Teratology, 1985, 32, 133-144.
26. Nishimura M., Maeda M., Matsuoka M. i wsp.: Tumor necrosis factor, tumor necrosis factor receptors type 1 and 2, lymphotoxin-alpha, and HLA-DRB1 gene polymorphisms in human T-cell lymphotropic virus type I associated myelopathy. Hum. Immunol., 2000, 61, 1262-1269.
27. Nophar Y., Kemper O., Brakebusch C. i wsp.: Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor. EMBO J., 1990, 9, 3269-3278.
28. Peschon J.J., Slack J.L., Reddy P. i wsp.: An essential role for ectodomain shedding in mammalian development. Science, 1998, 282, 281-284.
29. Rothe M., Pan M.G., Henzel W.J. i wsp.: The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. Cell, 1995, 83, 1243-1252.
30. Sariban E., Imamura K., Luebbers R. i wsp.: Transcriptional and post-transcriptional regulation of tumor necrosis factor gene expression in human monocytes. J. Clin. Invest., 1988, 81, 1506-1510.
31. Schwab J.M., Schluesener H.J., Meyermann R. i wsp.: COX-3 the enzyme and the concept: steps towards highly specialized pathways and precision therapeutics? Prostaglandins Leukot. Essent. Fatty Acids, 2003, 69, 339-343.
32. Shear M.J., Turner F.C., Perrault A.: Chemical treatment of tumors. V. Isolation of the hemorrhage producing fraction from Serratia marcesens culture filtrates. J. Natl. Cancer Inst., 1943, 4, 81-97.
33. Vila-del Sol V., Fresno M.: Involvement of TNF and NF-kappa B in the transcriptional control of cyclooxygenase-2 expression by IFN-gamma in macrophages. J. Immunol., 2005, 74, 2825-2833.
34. Ware C.F., van Arsdale S., van Arsdale T.L.: Apoptosis mediated by the TNF-related cytokine and receptor families. J. Cell Biochem., 1996, 60, 47-55.
35. Xu J., Cissel D.S., Varghese S. i wsp.: Cytokine regulation of adult human osteoblast-like cell prostaglandin biosynthesis. J. Cell. Biochem., 1997, 64, 618-631.